PHARMACEUTICAL IP

  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapy
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Our offering

At Evolve, we provide specialised IP strategy services tailored to the unique needs of pharmaceutical and biotechnology companies at every stage of development. Our approach combines scientific expertise with commercial insight to deliver practical intellectual property solutions that drive business value. We understand that effective IP strategy must be both deeply rooted in the science and adapt alongside your company’s growth.

With extensive industry experience and technical knowledge, we are passionate about supporting our clients to realise the full potential of their innovations.

 

Find out more

Evolve IP is able to offer commercially focused, strategic, and clear advice on complex patent portfolios

The team are thoughtful and intuitive and provide a personable service.

Evolve are friendly and knowledgeable and provide practical advice.

I chose Evolve because they have unique expertise in pharma IP. They are friendly and knowledgeable and provide practical advice.

I recommend Evolve for chemical/pharma patent issues – whether prosecution or complex FTO or loss of exclusivity considerations.

Evolve Intellectual Property offers expertise in patent portfolio management, strategic planning and formalities.

Evolve Intellectual Property is a growing firm, with an excellent reputation.

Evolve is a refreshing change to the traditional patent attorney form approach – much more nimble and responsive.

Fractional in-house

Do you need experienced IP leadership without the overhead of a full-time in-house team?

Our fractional in-house service delivers the senior head of IP expertise you require on a flexible and cost-effective basis, allowing you to scale your IP function precisely when and how you need it. We understand the critical role intellectual property plays in your growth and offer a tailored approach to align your IP strategy directly with your overarching business objectives. Our fractional in-house service seamlessly integrates with your existing team, becoming a trusted partner in managing your day-to-day IP needs. By working with us you will benefit from strategically managed intellectual property helping you to foster innovation, secure investment and gain a competitive edge.

With Evolve you access experienced IP leadership when you need it. Think of us as your dedicated, senior IP resource, readily available to handle the operational complexities while providing expert strategic direction.

Find out more

Sectors

Our team’s combined experience spans traditional pharmaceuticals to cutting-edge advanced therapies, providing you with guidance that is both scientifically informed and commercially pragmatic.

 

Find out more
  • Pharmaceuticals
  • Biotech
  • Biologics
  • Cell & gene therapy
  • AI drug discovery
  • Chemistry

Insights

Visit Evolve Insights for our latest articles and webinars on key emerging trends and strategic considerations in pharmaceutical IP.

Read more

Evolve Intellectual Property ranked in IAM Patent 1000

  • 13th September 2026
We are proud to announce that Evolve IP has been ranked in the 2026 publication of the IAM Patent 1000: United Kingdom – England and Wales. This year’s guide highlights our deep technical expertise in life sciences and our practical, strategic business focus. Congratulations to our patent attorneys, Steven Gurney who is ranked Silver and Rose…

IP Stars: Evolve recognised in 2026 Publication

  • 13th September 2026
We are delighted to announce that Evolve IP has been recognised in the 2026 IP STARS rankings. This distinction reflects our team’s ongoing dedication to exceptional intellectual property support, featuring key individual accolades for our patent attorneys. Steven Gurney has been recognised as a Patent Star. This specific ranking is awarded to senior practitioners who demonstrate proven excellence in…

Evolve Intellectual Property recognised in Legal500 rankings

  • 13th September 2026
Evolve Intellectual property is delighted to once again be recognised in the 2026 edition of Legal 500 for our growing specialised life science IP Practice in Cambridge, UK. The publication highlights Steven Gurney (founder and European, UK, and Australian patent attorney) for his work protecting key biopharmaceutical assets and for his focus on complex prosecution…

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.

AI in the patent industry: Beware the MCP Trojan horse

  • 11th September 2026
As patent attorneys, we should all know by now not to put client confidential information to a non-enterprise version of an LLM. However, as the capabilities of AI tools become more complex, so too does the necessity of understanding what exactly they are doing and where our data goes, beyond the simple prompt.

Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026)

  • 8th September 2026
The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target and indication from rival innovator companies, not copycat products with identical CAR sequences.

Our team

Evolve is a pharmaceutical specialist IP firm, offering comprehensive intellectual property services built on the experience of our attorneys in both in-house and private practice settings. Evolve is built on the deep expertise of our qualified attorneys in the pharmaceutical and biotech sector. With our personalized approach, scientific backgrounds and industry insights, we deliver tailored and pragmatic IP solutions for our pharmaceutical and biotechnology clients.

Meet the team

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us